
PI3K/Akt/mTOR Signaling
PI3K/Akt/mTOR signaling inhibitors are compounds that target the phosphoinositide 3-kinase (PI3K), Akt kinase, and mammalian target of rapamycin (mTOR) pathways. These pathways are critical regulators of cell growth, survival, metabolism, and autophagy, making them key targets in cancer research and metabolic disorders. Inhibiting these pathways can help to control tumor growth and proliferation, offering potential therapeutic strategies for various cancers and other diseases characterized by dysregulated cell signaling. At CymitQuimica, we offer a comprehensive selection of high-quality PI3K/Akt/mTOR inhibitors to support your research in oncology, cellular signaling, and metabolic diseases.
Subcategories of "PI3K/Akt/mTOR Signaling"
- AMPK(159 products)
- ATM/ATR(71 products)
- DNA-PK(50 products)
- EGFR(572 products)
- MELK(7 products)
- PDK(9 products)
- PI3K(241 products)
- S6 Kinase(9 products)
- gsk-3(111 products)
- mTOR(144 products)
Show 2 more subcategories
Found 1030 products of "PI3K/Akt/mTOR Signaling"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Formula:C29H26FN5O3SPurity:98%Color and Shape:SolidMolecular weight:543.61JBJ-09-063 hydrochloride
<p>JBJ-09-063 hydrochloride: targeted EGFR inhibitor, effective for various mutations and TKI-resistant lung cancer models.</p>Formula:C31H30ClFN4O3SColor and Shape:SolidMolecular weight:593.11NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Formula:C22H20O4Color and Shape:SolidMolecular weight:348.39TCS 2002
CAS:<p>GSK-3β inhibitor 9b: potent, selective, oral, IC50=35 nM, good pharmacokinetics, BBB-permeable, researched for Alzheimer's.</p>Formula:C18H14N2O3SColor and Shape:SolidMolecular weight:338.38BRD3731
CAS:<p>BRD3731 selectively inhibits GSK3β with IC50 of 15 nM; it's promising for PTSD, psychiatric issues, diabetes, and neurodegeneration.</p>Formula:C24H31N3OColor and Shape:SolidMolecular weight:377.52EGFR-IN-25
CAS:<p>EGFR-IN-25, an efficacious EGFR inhibitor, demonstrates IC50 values of 9 nM for BaF3 cells (EGFR DEL19/T790M/C797S) and 60 nM for A431 cells (WT), respectively.</p>Formula:C34H43N9O2Color and Shape:SolidMolecular weight:609.76PIKfyve-IN-2
CAS:<p>PIKfyve-IN-2 is a potent inhibitor of the PIKfyve kinase, with potential applications in cancer and autoimmune disorder research [1].</p>Formula:C22H22N8OColor and Shape:SolidMolecular weight:414.46Epertinib
CAS:<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Formula:C30H27ClFN5O3Purity:98%Color and Shape:SolidMolecular weight:560.02EGFR-IN-67
CAS:<p>EGFR-IN-67 (Compound 7d) is a potent inhibitor of EGFR with anticancer activity (IC 50 = 0.34 μM) [1].</p>Formula:C18H17N3SColor and Shape:SolidMolecular weight:307.41PI3K-IN-10
CAS:<p>PI3K-IN-10 is a potent inhibitor of pan-PI3K .</p>Formula:C23H19ClN6OPurity:98%Color and Shape:SolidMolecular weight:430.89DNA-PK-IN-1
CAS:<p>DNA-PK-IN-1 is a potent inhibitor of DNA-PK. DNA-PK-IN-1 has potential for cancer disease research.</p>Formula:C23H26N8O2Color and Shape:SolidMolecular weight:446.5EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Formula:C20H21N3O3Color and Shape:SolidMolecular weight:351.4GW 583340 dihydrochloride
CAS:<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Formula:C28H27Cl3FN5O3S2Purity:98.80%Color and Shape:SolidMolecular weight:671.03(R)-PS210
CAS:(R)-PS210, the R enantiomer of PS210 is a substrate-selective allosteric PDK1 activator with an (AC50 of 1.8 μM).Formula:C19H15F3O5Color and Shape:SolidMolecular weight:380.31FD2056
CAS:<p>FD2056 is a potent, orally active PI3K inhibitor, with IC50 values of 0.30, 0.80, 1.10, and 0.42 nM against PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively.</p>Formula:C23H17ClN6O2SPurity:98%Color and Shape:SolidMolecular weight:476.94EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Formula:C26H31FN8O2SPurity:98%Color and Shape:SolidMolecular weight:538.64EGFR-IN-5
CAS:<p>EGFR-IN-5 inhibits EGFR & mutants; IC50: EGFR 10.4nM, L858R 1.1nM, L858R/T790M 34nM, L858R/T790M/C797S 7.2nM.</p>Formula:C31H38FN9OPurity:98.17%Color and Shape:SolidMolecular weight:571.69PI3-Kinase α Inhibitor 2
CAS:<p>Phosphatidylinositol 3-kinase (PI3K) catalyzes the phosphorylation of the 3' hydroxyl position of PIs to produce the second messengers PtdIns-(3,4)-P2 and</p>Formula:C16H15N3O2SColor and Shape:SolidMolecular weight:313.37PI3K/mTOR Inhibitor-3
CAS:<p>PI3K/mTOR Inhibitor-3, a potent dual-action anti-cancer imidazoline, targets PI3K and mTOR.</p>Formula:C22H23N5OColor and Shape:SolidMolecular weight:373.45EGFR-IN-54
CAS:<p>EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.</p>Formula:C17H14N4O4S3Color and Shape:SolidMolecular weight:434.51
